AG
ALNY icon

AlphaSimPlex Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

AlphaSimPlex Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,508
Closed -$213K – 222
2021
Q1 		$213K Sell
1,508
-472
-24% -$71K 0.09% 245
2020
Q4 		$257K Sell
1,980
-425
-18% -$56.7K 0.09% 286
2020
Q3 		$350K Buy
2,405
+828
+53% +$118K 0.16% 223
2020
Q2 		$234K Buy
+1,577
New +$213K 0.18% 222

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AlphaSimPlex Group's ALNY Position: Q2 2021 in Review

AlphaSimPlex Group sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2021, closing a stake of 1,508 shares — an estimated $213K sold.

AlphaSimPlex Group first reported a position in ALNY in Q2 2020 and held it in 4 quarters. The position peaked at $350K in Q3 2020. 401 funds tracked by Wall St. Rank hold ALNY as of Q2 2021.

  • AlphaSimPlex Group reported no remaining Alnylam Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • AlphaSimPlex Group sold 1,508 Alnylam Pharmaceuticals shares in Q2 2021, an estimated $213K.
  • AlphaSimPlex Group first reported a position in Alnylam Pharmaceuticals in Q2 2020 and held it in 4 quarters.
  • AlphaSimPlex Group's Alnylam Pharmaceuticals position peaked at $350K in Q3 2020.
  • 401 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2021.

Based on AlphaSimPlex Group's 13F filing for Q2 2021, filed 12 Aug 2021.